Science 37 Holdings Inc Stock Price, News & Analysis

Welcome to our dedicated page for Science 37 Holdings news (Ticker: SNCE), a resource for investors and traders seeking the latest updates and insights on Science 37 Holdings stock.

Science 37 Holdings, Inc. (SNCE) is frequently featured in clinical research news for its role in expanding patient access to trials through virtual and direct-to-patient models. Company announcements highlight its Metasite™ Virtual Site, Direct-to-Patient Site, and Patient Recruitment solutions, which are used by clinical trial sponsors and CROs to address enrollment and study conduct challenges across a range of therapeutic areas.

News about Science 37 often focuses on its participation in Phase 2 and Phase 3 studies, including rare disease, asthma, infectious disease, and immunocompromised patient cohorts. The company has reported contributing significant portions of total enrollment in pivotal trials, as well as helping under-enrolling studies trend back toward projected recruitment targets. These updates provide insight into how its decentralized and virtual site models function in real-world clinical programs.

Another recurring theme in Science 37 news is regulatory oversight and quality. The company has disclosed multiple FDA inspections of its Metasite™ and Direct-to-Patient Site models, with outcomes described as No Action Indicated and no Form 483s issued. Coverage of these inspections details how regulators have reviewed internal processes, technology platforms, data integrity, subject safety, and Principal Investigator oversight.

Investors and industry observers following SNCE news can expect updates on new partnerships with sponsors and service providers, case studies on enrollment performance, and developments related to its headquarters and operational footprint in Morrisville, North Carolina. This news stream offers context on how Science 37’s virtual and direct-to-patient approaches are being applied across different studies and therapeutic areas.